Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2015
July 2015, Vol 6, No 6
July 2015, Vol 6, No 6
Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma
By
Lisa A. Raedler, PhD, RPh
Drug Updates
,
Multiple Myeloma
July 2015, Vol 6, No 6
Multiple myeloma, also referred to as myeloma, is a cancer of plasma cells in the bone marrow that often leads to bone destruction and bone marrow failure. According to the American Cancer Society, more than 26,800 new cases of multiple myeloma will be diagnosed in 2015, and 11,240 deaths will be attributed to this disease.
Read Article
Value-Based Oncology: The Intersection of Drug Costs, Effectiveness, and Toxicity
By
Roy Beveridge, MD
;
William K. Fleming, PharmD
;
Bryan Loy, MD, MBA
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
July 2015, Vol 6, No 6
Value-based oncology was one of the high-profile topics at the 2015 American Society of Clinical Oncology (ASCO) meeting. It is something that is discussed widely in print and on social media. It is certainly top of mind for payers, doctors, policymakers, business leaders, and, in particular, patients.
Read Article
Genetic Abnormality Pinpointed for Intensive Therapy in Wilms Tumor
By
Phoebe Starr
ASCO 2015 Highlights
,
ASCO
July 2015, Vol 6, No 6
Chicago, IL—In children who are at risk for Wilms tumor, the presence of a rare genetic abnormality identifies children who can have a survival benefit from the augmentation or intensification of therapy. The abnormality—loss of heterozygosity (LOH) on chromosomes 1p and 16q (LOH 1p/16q)—is associated with worse prognosis in children with Wilms tumor.
Read Article
Two Large National Personalized Medicine Clinical Trials Are Launched by ASCO and NCI
By
Dana Taylor
ASCO 2015 Highlights
,
ASCO
July 2015, Vol 6, No 6
Chicago, IL—Precision medicine in oncology is now being studied in clinical trials in oncology. These trials will pair a patient’s tumor molecular profile with drugs that address those tumor variants.
Read Article
Lenvatinib Extends Survival in Metastatic Renal-Cell Carcinoma
By
Wayne Kuznar
ASCO 2015 Highlights
,
ASCO
July 2015, Vol 6, No 6
Chicago, IL—Lenvatinib (Lenvima) added to everolimus (Afinitor) extended overall survival (OS) significantly compared with everolimus alone in patients with metastatic renal-cell carcinoma (RCC). This phase 2 study also demonstrated improved progression-free survival (PFS) with lenvatinib alone and in combination with everolimus compared with everolimus alone.
Read Article
Current Cost of Cancer Drugs Does Not Reflect Value, One Oncologist Suggests
By
Dana Taylor
ASCO 2015 Highlights
,
ASCO
July 2015, Vol 6, No 6
Chicago, IL—According to Leonard B. Saltz, MD, Chief of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center, NY, the cost of new cancer drugs is no longer sustainable. Dr Saltz presented “Perspectives on Value” at the Plenary Session of the 2015 American Society of Clinical Oncology meeting.
Read Article
The Push Toward Value-Based Payment for Oncology
By
Wayne Kuznar
Value in Oncology
July 2015, Vol 6, No 6
Chicago, IL—A transition from reimbursement based on volume to reimbursement based on value has begun to emerge, said speakers at the 2015 American Society of Clinical Oncology meeting in a session on payment reform. The transition will be clumsy, with competing and potentially mutually exclusive incentives.
Read Article
Value Propositions in Oncology: The Physician Perspective
By
Chase Doyle
Value in Oncology
,
Value Propositions
,
Value Peer-spectives
July 2015, Vol 6, No 6
Chicago, IL—The rising costs of cancer drugs and medical services, along with increased copays and high deductibles for patients, are adding a serious financial hardship to patients diagnosed with cancer, according to Neal J. Meropol, MD, Associate Director, Clinical Programs, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH.
Read Article
Anthem’s Clinical Pathways Demonstrate Value: The Payer Perspective
By
Chase Doyle
Clinical Pathways
,
Value in Oncology
July 2015, Vol 6, No 6
Chicago, IL—At the special session on value during the 2015 American Society of Clinical Oncology meeting, Jennifer Malin, MD, PhD, Staff Vice President for Clinical Strategy, Anthem, Thousand Oaks, CA, presented the payer perspective on value in cancer care. The role of the payer, Dr Malin said, is to balance different stakeholders’ values and needs at various time points.
Read Article
The Search for Value-Based Healthcare Delivery: The Agenda for Oncology
By
Chase Doyle
Value in Oncology
July 2015, Vol 6, No 6
Chicago, IL—The presidential keynote address at the 2015 American Society of Clinical Oncology meeting was presented by Michael E. Porter, PhD, MBA, Bishop William Lawrence University Professor, Harvard Business School, Boston, who started the value discussions a decade ago. A strong proponent of changing the healthcare system to focus on value, Dr Porter suggests that the fundamental purpose of healthcare is to deliver great outcomes with increasing efficiency, but achieving this goal requires more holistic thinking about delivery care as science.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma